Aktis Oncology Statistics
Total Valuation
Aktis Oncology has a market cap or net worth of $905.49 million. The enterprise value is $423.39 million.
| Market Cap | 905.49M |
| Enterprise Value | 423.39M |
Important Dates
The last earnings date was Thursday, November 12, 2026, before market open.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Aktis Oncology has 55.62 million shares outstanding. The number of shares has increased by 4,956.81% in one year.
| Current Share Class | 53.75M |
| Shares Outstanding | 55.62M |
| Shares Change (YoY) | +4,956.81% |
| Shares Change (QoQ) | +0.63% |
| Owned by Insiders (%) | 0.46% |
| Owned by Institutions (%) | 42.94% |
| Float | 28.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 73.11 |
| Forward PS | 150.15 |
| PB Ratio | 1.98 |
| P/TBV Ratio | 1.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 34.18 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.22, with a Debt / Equity ratio of 0.02.
| Current Ratio | 14.22 |
| Quick Ratio | 14.02 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -26.53% and return on invested capital (ROIC) is -19.00%.
| Return on Equity (ROE) | -26.53% |
| Return on Assets (ROA) | -15.98% |
| Return on Invested Capital (ROIC) | -19.00% |
| Return on Capital Employed (ROCE) | -20.86% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $156,785 |
| Profits Per Employee | -$1.11M |
| Employee Count | 79 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 18.74 |
| 200-Day Moving Average | 20.79 |
| Relative Strength Index (RSI) | 46.15 |
| Average Volume (20 Days) | 347,615 |
Short Selling Information
The latest short interest is 4.43 million, so 7.96% of the outstanding shares have been sold short.
| Short Interest | 4.43M |
| Short Previous Month | 4.31M |
| Short % of Shares Out | 7.96% |
| Short % of Float | 15.48% |
| Short Ratio (days to cover) | 13.35 |
Income Statement
In the last 12 months, Aktis Oncology had revenue of $12.39 million and -$87.55 million in losses. Loss per share was -$2.18.
| Revenue | 12.39M |
| Gross Profit | -55.07M |
| Operating Income | -103.73M |
| Pretax Income | -87.55M |
| Net Income | -87.55M |
| EBITDA | -100.56M |
| EBIT | -103.73M |
| Loss Per Share | -$2.18 |
Balance Sheet
The company has $492.93 million in cash and $10.84 million in debt, with a net cash position of $482.09 million or $8.67 per share.
| Cash & Cash Equivalents | 492.93M |
| Total Debt | 10.84M |
| Net Cash | 482.09M |
| Net Cash Per Share | $8.67 |
| Equity (Book Value) | 458.87M |
| Book Value Per Share | 8.23 |
| Working Capital | 464.73M |
Cash Flow
In the last 12 months, operating cash flow was -$86.12 million and capital expenditures -$8.04 million, giving a free cash flow of -$94.16 million.
| Operating Cash Flow | -86.12M |
| Capital Expenditures | -8.04M |
| Depreciation & Amortization | 3.17M |
| Net Borrowing | n/a |
| Free Cash Flow | -94.16M |
| FCF Per Share | -$1.69 |
Margins
| Gross Margin | n/a |
| Operating Margin | -837.45% |
| Pretax Margin | -706.81% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Aktis Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4,956.81% |
| Shareholder Yield | -4,956.81% |
| Earnings Yield | -13.40% |
| FCF Yield | -10.40% |
Analyst Forecast
The average price target for Aktis Oncology is $35.88, which is 120.39% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $35.88 |
| Price Target Difference | 120.39% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 14.54% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |